Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate

Investigative Radiology

Volumn 42, Issue 2, 2007, Pages 116-122

  Fütterer, Jurgen J ^a,b   Scheenen, Tom W J ^a   Heijmink, Stijn W T P J ^a   Huisman, Henkjan J ^a   Hulsbergen Van De Kaa, Christina A ^a   Witjes, J Alfred ^a   Heerschap, Arend ^a   Barentsz, Jelle O ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Prostate neoplasms; Spectroscopic imaging (MRSI)

Indexed keywords

PROSTATE ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

EID: 33846213155     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000251541.03822.bb     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55:10-30.
2. Stewart SL, King JB, Thompson TD, et al. Cancer mortality surveillance - United States, 1990-2000. MMWR Surveill Summ. 2004;53:1-108.
3. Kurhanewicz J, Vigneron DB, Hricak H, et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0. 24-0.7-cm3) spatial resolution. Radiology. 1996;198:795-805.
4. Heerschap A, Jager GJ, van der Graaf M, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17:1455-1460.
5. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804-814.
6. Huisman HJ, Fütterer JJ, van Lin EN, et al. Precision of integrating functional magnetic resonance in radiotherapy treatment of prostate cancer using fiducial gold markers registration methods. Radiology. 2005;236:311-317.
7. Scheenen TW, Klomp DW, Roll SA, et al A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med. 2004;52:80-88.
8. Zakian KL, Eberhardt S, Hricak H, et al. Transition zone prostate cancer: metabolic characteristics at H MR spectroscopic imaging - initial results. Radiology. 2003;229:241-247.
9. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006;239:784-792.
10. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology. 1999;213:473-480.
11. Jung J, Coakley FV, Vigneron DV, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology. 2004;233:701-708.
12. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987;508:333-384.
13. Scheenen TWJ, Weiland E, Fütterer JJ, et al. Preliminary results of IMAPS: an international multi-centre assessment of prostate MR spectroscopy. Presented at the 13th Scientific Meeting of the International Society for Magnetic Resonance in Medicine, Miami, FL. 2005.
14. Greene F, Page D, Fleming I, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag, 2002.
15. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933-938.
16. Augustin H, Hammerer PG, Graefen M, et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol. 2003;43:455-460.
17. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
18. Obuchowski NA, Lieber ML, Powell KA. Data analysis for detection and localization of multiple abnormalities with application to mammography. Acad Radiol. 2000;7:516-525.
19. Rutter CM. Bootstrap estimation of diagnostic accuracy with patient-clustered data. Acad Radiol. 2000;7:413-419.
20. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
21. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002;223:91-97.
22. Chen ME, Johnston DA, Tang K, et al. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer. 2000;89:1800-1809.
23. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and distribution of spread. Am J Surg Pathol. 1988;12:804-814.
24. Fleshner NE, Fair WR. Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol. 1997;157:556-558.
25. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
26. Cookson MS, Fleshner NE, Soloway SM, et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997;157:559-562.
27. Steinberg DM, Sauvageot J, Piantadosi S, et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997;21:566-576.
28. Hricak H. MR imaging and MR spectroscopic imaging in the pretreatment evaluation of prostate cancer. Br J Radiol. 2005;78:S103-S111.
29. van Dorsten FA, van der Graaf M, Engelbrecht MR, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004;20:279-287.
30. Beyersdorff D, Winkel A, Hamm B, et al. MR Imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology. 2005;234:576-581.
31. Anastasiadis AG, Lichy MP, Nagele U, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol. 2006;50:738-749.
32. Prando A, Kurhanewicz J, Borges AP, et al. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific anigen levels and prior negative biopsy findings: early experience. Radiology. 2005;236:903-910.
33. Van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291-303.